Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POINT: Pembrolizumab and olaparib in platinum‑resistant recurrent/metastatic nasopharyngeal cancer
2024-511901-52-00Phase 2Authorised
- Sponsor
- GONO Foundation
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and olaparib in nasopharyngeal carcinoma (NPC), sponsored by GONO Foundation. Primary endpoint: Objective Response Rate (ORR) by week 27 per RECIST 1.1. Planned start Oct 2024; status: authorised.
02
Drugs
pembrolizumabolaparib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on 2024-511901-52-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511901-52-00.